INO INOVIO PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1055726 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.0%
TTM net income YoY20.8%
TTM EPS YoY54.2%
Revenue 3-yr CAGR-81.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-132,871.3%
Net margin-130,000.0%
FCF margin-136,074.5%
EBITDA margin-130,701.4%
Returns
ROE-183.5%
ROA-90.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio3.9%
Payout ratio—
Capex / revenue437.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $65,343 | $217,756 |
| R&D expense | $54.21M | $75.62M |
| SG&A expense | $32.68M | $37.00M |
| Operating income | -$86.82M | -$112.40M |
| Interest expense | $0 | $177,833 |
| Pretax income | -$84.95M | -$107.25M |
| Income tax | $0 | $0 |
| Net income | -$84.95M | -$107.25M |
| EBITDA | -$85.40M | -$110.65M |
| EPS (basic) | -1.81 | -3.95 |
| EPS (diluted) | -1.81 | -3.95 |
| Weighted avg. shares (diluted) | 46.89M | 27.16M |
| Balance sheet | ||
| Cash & equivalents | $44.27M | $65.81M |
| Short-term investments | $14.24M | $28.30M |
| Receivables | $450 | $1.20M |
| Current assets | $61.12M | $97.83M |
| PP&E, net | $2.53M | $3.66M |
| Total assets | $74.31M | $113.20M |
| Current liabilities | $43.67M | $35.33M |
| Total liabilities | $50.21M | $44.69M |
| Shareholders' equity | $24.10M | $68.50M |
| Shares outstanding | 69.00M | 36.10M |
| Cash flow statement | ||
| Operating cash flow | -$88.63M | -$104.08M |
| Capital expenditure | $285,698 | $487,832 |
| Free cash flow | -$88.92M | -$104.56M |
| Investing cash flow | $14.04M | $104.07M |
| Financing cash flow | $53.05M | $51.48M |
| Depreciation & amortization | $1.42M | $1.75M |
| Stock-based compensation | $3.76M | $6.60M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.